ADVFN US – Market Content Editor
-

Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease
Belite Bio Inc ADR (NASDAQ:BLTE) leapt 17.1% in premarket trading Monday after unveiling strong Phase 3 results for Tinlarebant — the first pivotal clinical trial to show efficacy in Stargardt disease, a rare inherited condition that causes progressive vision loss and currently has no approved therapies. The late-stage DRAGON study achieved its main goal, showing…
-

Cullinan Oncology Shares Tick Higher After AML Therapy Secures FDA Fast Track Status
Cullinan Therapeutics (NASDAQ:CGEM) saw its stock rise 2.9% in Monday’s premarket session after announcing that the U.S. Food and Drug Administration has awarded Fast Track designation to CLN-049, its investigational treatment for relapsed or refractory acute myeloid leukemia (AML). The Cambridge-based biotech said the designation demonstrates both the seriousness of AML and the need for…
-

Massimo Shares Jump After Company Adopts Bitcoin as Part of Treasury Strategy
Massimo Group (NASDAQ:MAMO) rallied 18% on Monday after unveiling a new treasury initiative that will incorporate Bitcoin into its long-term balance sheet management. The powersports manufacturer said its Board of Directors has formally approved the use of Bitcoin as a treasury reserve asset, and initial purchases have already begun. Massimo said it will report its…
-

Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal
Omeros Corporation (NASDAQ:OMER) surged 12% on Monday after the company confirmed it has officially completed its asset purchase and license agreement with Novo Nordisk for zaltenibart, its clinical-stage MASP-3 inhibitor. The agreement, first unveiled on October 15, delivers an upfront cash payment of $240 million, which Omeros has already received. In total, the company could…
-

Laser Photonics Shares Slide After Nasdaq Flags Filing Delay
Laser Photonics Corp. (NASDAQ:LASE) saw its stock drop 8.3% in premarket trading on Monday after revealing it had received a non-compliance notice from Nasdaq tied to a delayed quarterly filing. The company said Nasdaq informed it on November 20, 2025, that it was out of compliance with listing standards because it had not submitted its…
-

Marvell Shares Gain as Microsoft Expands Azure Security Partnership Across Europe
Marvell Technology (NASDAQ:MRVL) traded 1.6% higher on Monday morning, outperforming the broader market after the chipmaker revealed an expanded security partnership with Microsoft (NASDAQ:MSFT) focused on strengthening cloud protections in Europe. The company said Microsoft is broadening its adoption of Marvell’s LiquidSecurity hardware security modules (HSMs), enabling Azure to offer additional cloud-based security services to…
-

Kala Bio Shares Jump After $6 Million Funding Deal With Investor David Lazar
KALA BIO, Inc. (NASDAQ:KALA) soared 28.3% in premarket trading on Monday after revealing that it has entered into a $6 million securities purchase agreement with private investor David E. Lazar. The company said it has already received $1.8 million from the first tranche of the two-part investment. As part of the deal, Lazar has taken…
-

Wolfspeed Shares Jump After Securing $698.6 Million IRS Refund
Wolfspeed Inc. (NYSE:WOLF) saw its stock climb 10.4% in premarket trading on Monday after announcing it has received $698.6 million in cash tax refunds from the Internal Revenue Service. The refund was issued under the Advanced Manufacturing Investment Credit in Section 48D of the U.S. tax code and accounts for a sizable portion of the…
-

Intercont (Cayman) Shares Skyrocket After Announcing Major Low-Carbon Shipping Partnership
Intercont (Cayman) Limited (NASDAQ:NCT) surged 47% in premarket trading on Monday after the company unveiled a new strategic partnership between its Singapore subsidiary, Openwindow, and CINCO INTERNATIONAL HONGKONG LIMITED. The collaboration is expected to deliver roughly $118.25 million in cumulative contract revenue and an estimated $88.96 million in cumulative net profit. The agreement focuses on…
-

ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy
ProMIS Neurosciences Inc. (NASDAQ:PMN) rose 6% on Monday after new research findings bolstered confidence in the company’s biomarker-focused approach to Alzheimer’s disease drug development. The company said a peer-reviewed paper published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions found that plasma phosphorylated tau (pTau) biomarkers may serve as reliable early indicators of clinical…